S 488410

Drug Profile

S 488410

Alternative Names: S-488410

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Shionogi
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2012 Shionogi completes enrolment in a phase I/II trial in Oesophageal cancer in Japan
  • 14 Feb 2011 S 488410 is still in phase-I/II trials for Oesophageal cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top